An observational study in Hepatocellular Carcinoma (HCC), sponsored by Beijing Tsinghua Chang Gung Hospital. Not yet recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital — 8 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · Beijing Tsinghua Chang Gung Hospital.
Among the 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital, this one is one of 2 that started in 2026, is one of 9 observational ones, and was the 18th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →8 of the 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18+
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18+
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–70
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–70
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 851 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 24 across the 9 interventional studies, 300 across the 9 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 111 studies on the registry; 59 are open to participants now.
2 of the studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07070362Beijing Tsinghua Chang Gung HospitalDigital Early Warning System for Acute Lung Injury in Liver Surgery | 2027-06-01 |
| NCT07058649Beijing Tsinghua Chang Gung HospitalDownstaging Prediction Model for HCC | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Carcinoma, Hepatocellular by Beijing Tsinghua Chang Gung Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.
This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.
The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable.
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable.
Postoperative recurrence-free survival (RFS)
Time frame: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
Postoperative overall survival (OS)
Time frame: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
Pathological complete response (pCR) rate
pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments.
Time frame: Immediately after curative-intent hepatectomy.
Major pathological response (MPR) rate
MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments.
Time frame: Immediately after curative-intent hepatectomy.
Microvascular invasion (MVI) positivity rate
Time frame: Immediately after curative-intent hepatectomy.
Satellite nodule positivity rate
Time frame: Immediately after curative-intent hepatectomy.
Postoperative complication rate
The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria.
Time frame: Perioperatively, from curative-intent hepatectomy through hospital discharge.
Percentage change in tumor markers
Time frame: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
Percentage change in maximum tumor diameter
Time frame: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
Plan to share: Yes — De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.
Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 60 months is above that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tsinghua Chang Gung Hospital →